<?xml version="1.0" encoding="UTF-8"?>
<p id="Par24">Major clinical guidelines recommended the third trimester as the inception date due to inadequate evidence of safety in human data evaluated in an earlier pregnancy. Previous study has published that LDT administrated throughout early, middle, or late pregnancy is safe and effective to interrupt mother-to-infant transmission [
 <xref ref-type="bibr" rid="CR39">39</xref>]. Therefore, it needs to define optimal timing to initiate antiviral prophylaxis to completely prevent MTCT of HBV during pregnancy [
 <xref ref-type="bibr" rid="CR45">45</xref>].
</p>
